These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30026012)

  • 1. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
    Marchese U; Ewald J; Gilabert M; Delpero JR; Turrini O
    J Visc Surg; 2019 Apr; 156(2):97-101. PubMed ID: 30026012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
    Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
    Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.
    Agalianos C; Gouvas N; Papaparaskeva K; Dervenis C
    HPB (Oxford); 2016 Aug; 18(8):633-41. PubMed ID: 27485057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemotherapy.
    Yee EJ; Torphy RJ; Thielen ON; Easwaran L; Franklin O; Sugawara T; Bartsch C; Garduno N; McCarter MM; Ahrendt SA; Schulick RD; Del Chiaro M
    Ann Surg Oncol; 2024 Sep; 31(9):6127-6137. PubMed ID: 38780693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
    Garnier J; Magallon C; Ewald J; Palen A; Marchese U; Delpero JR; Turrini O
    Langenbecks Arch Surg; 2022 May; 407(3):1065-1071. PubMed ID: 34705107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
    Kozak GM; Epstein JD; Deshmukh SP; Scott BB; Keith SW; Lavu H; Yeo CJ; Winter JM
    J Gastrointest Surg; 2018 Feb; 22(2):288-294. PubMed ID: 29139084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
    Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
    Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505.
    Cloyd JM; Colby S; Guthrie KA; Lowy AM; Chiorean EG; Philip P; Sohal D; Ahmad S
    J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38688309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer.
    Okada K; Uemura K; Kondo N; Sumiyoshi T; Seo S; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Murakami Y; Takahashi S
    Pancreatology; 2021 Apr; 21(3):606-612. PubMed ID: 33648880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Yuasa Y; Sueda T
    World J Surg; 2010 Aug; 34(8):1900-7. PubMed ID: 20376442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
    Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
    Kaissis G; Ziegelmayer S; Lohöfer F; Steiger K; Algül H; Muckenhuber A; Yen HY; Rummeny E; Friess H; Schmid R; Weichert W; Siveke JT; Braren R
    PLoS One; 2019; 14(10):e0218642. PubMed ID: 31577805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma.
    Komo T; Murakami Y; Kondo N; Uemura K; Hashimoto Y; Nakagawa N; Urabe K; Takahashi S; Sueda T
    Ann Surg Oncol; 2016 Jun; 23(6):2019-27. PubMed ID: 26856722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.